Biocytogen 

Animal Models and Cell Lines

>Single Humanized Immune-Checkpoint Mice
B-hCD47 mice
CD47 is widely expressed on cell surface and interacts with the signal regulatory protein α (SIRPα), thrombospondin-1 (TSP1) and integrins to mediate a series of responses including apoptosis, proliferation and immunity. CD47 is an important "self" mark on the cell surface and inhibits macrophagocytosis by interaction with SIRPα on macrophage surface. Animal studies have shown that a CD47 antibody is an effective treatment for multiple t ypes of tumors. CD47 is another target for tumor immunity following PD-1/PD-L1.
B-hCTLA4 mice
The inhibition of CTLA4 by its inhibitory antibodies enhances T cell activity. The CTLA4 antibody is the first FDA-approved antibody to treat advanced melanoma.
B-hTNFRSF18(GITR) mice
TNFRSF18 is up-regulated upon the activation of T cells, and in turn promotes T cell proliferation. CD25+/CD4+ regulatory T cell is known to mediate immune tolerance, and GITR agonist antibodies can reverse this immune tolerance, and show anti-tumor effect in multiple tumor models.
B-hLAG-3 mice
LAG3 is a negative regulator of immunity and mainly binds to MHC class Ⅱ molecules to regulate the function of dendritic cells. The expression of LAG3 is associated with the negative immunoregulatory function of specific T cells. Inhibition of LAG3 function enhances the anti-tumor effect of specific CD8+ T cells, therefore LAG3 is a potential target for tumor immunotherapy.
B-hTNFRSF4(OX40) mice
The coactivation of OX40/OX40L enhances T cell function, including cytokine production, proliferation and T cell survival. An OX40 agonist can reduce Regulatory T cells (Tregs) and improve anti-tumor activity.
B-hPD-1 mice
PD-1 interacts with its ligands and plays an important role in the negative regulation of the immune response.

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud